Analysis of a large patient cohort with nivolumab: Predictive clinical factors for continued benefit after an immune-related adverse event.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14600
Abstract: e14600Background: Nivolumab (NIVO), a PD-1 inhibitor, is used in various advanced malignancies with meaningful and durable outcomes. However, its use can be limited by severe immune-related adverse... read more here.
Keywords: analysis large; patient cohort; immune related; large patient ... See more keywords